Reema Wahdan-Alaswad
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Metformin | 5 | 2017 | 315 | 1.230 |
Why?
| Triple Negative Breast Neoplasms | 2 | 2016 | 197 | 0.780 |
Why?
| Breast Neoplasms | 5 | 2020 | 2142 | 0.730 |
Why?
| Thyroid Hormones | 1 | 2020 | 55 | 0.690 |
Why?
| Up-Regulation | 3 | 2020 | 840 | 0.680 |
Why?
| Tamoxifen | 1 | 2020 | 200 | 0.650 |
Why?
| Hormone Replacement Therapy | 1 | 2020 | 92 | 0.650 |
Why?
| TOR Serine-Threonine Kinases | 4 | 2013 | 396 | 0.640 |
Why?
| Receptors, Estrogen | 1 | 2020 | 426 | 0.570 |
Why?
| MicroRNAs | 2 | 2014 | 678 | 0.560 |
Why?
| Gene Expression Regulation, Neoplastic | 5 | 2016 | 1356 | 0.520 |
Why?
| Claudins | 1 | 2016 | 25 | 0.500 |
Why?
| Smad5 Protein | 2 | 2012 | 8 | 0.490 |
Why?
| Smad1 Protein | 2 | 2012 | 18 | 0.490 |
Why?
| Cell Line, Tumor | 10 | 2020 | 3215 | 0.470 |
Why?
| Cell Proliferation | 6 | 2017 | 2391 | 0.470 |
Why?
| Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.460 |
Why?
| Transcriptome | 1 | 2020 | 887 | 0.450 |
Why?
| Bone Morphogenetic Protein 4 | 2 | 2011 | 38 | 0.440 |
Why?
| Carcinogenesis | 1 | 2016 | 213 | 0.440 |
Why?
| Benzamides | 2 | 2017 | 207 | 0.440 |
Why?
| Receptor, ErbB-3 | 1 | 2013 | 45 | 0.430 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2013 | 209 | 0.380 |
Why?
| Prostatic Neoplasms | 4 | 2012 | 1016 | 0.380 |
Why?
| Receptor, ErbB-2 | 1 | 2013 | 326 | 0.360 |
Why?
| Apoptosis | 4 | 2014 | 2503 | 0.340 |
Why?
| Neoplastic Stem Cells | 1 | 2014 | 380 | 0.340 |
Why?
| Sirolimus | 1 | 2012 | 266 | 0.340 |
Why?
| Pyridines | 1 | 2013 | 478 | 0.330 |
Why?
| Glucose | 1 | 2013 | 1003 | 0.290 |
Why?
| Signal Transduction | 6 | 2016 | 4925 | 0.280 |
Why?
| Antineoplastic Agents | 3 | 2017 | 2061 | 0.270 |
Why?
| Disease-Free Survival | 2 | 2020 | 648 | 0.270 |
Why?
| Hypoglycemic Agents | 2 | 2017 | 1220 | 0.250 |
Why?
| Transforming Growth Factor beta | 3 | 2016 | 457 | 0.240 |
Why?
| Smad Proteins | 3 | 2016 | 38 | 0.240 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2020 | 814 | 0.220 |
Why?
| Gene Expression Profiling | 3 | 2016 | 1706 | 0.200 |
Why?
| Smad8 Protein | 2 | 2012 | 3 | 0.190 |
Why?
| RNA Interference | 3 | 2013 | 448 | 0.190 |
Why?
| Prostate | 2 | 2013 | 180 | 0.170 |
Why?
| MCF-7 Cells | 1 | 2020 | 116 | 0.170 |
Why?
| Mammary Neoplasms, Experimental | 2 | 2017 | 66 | 0.170 |
Why?
| Mice, SCID | 1 | 2020 | 351 | 0.160 |
Why?
| Cell Survival | 3 | 2012 | 1086 | 0.160 |
Why?
| Insulin-Like Growth Factor I | 2 | 2013 | 307 | 0.160 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2020 | 158 | 0.160 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 958 | 0.160 |
Why?
| Mice, Inbred NOD | 1 | 2020 | 588 | 0.150 |
Why?
| Blotting, Western | 2 | 2012 | 1205 | 0.150 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 857 | 0.150 |
Why?
| Organic Cation Transport Proteins | 1 | 2017 | 30 | 0.130 |
Why?
| Phosphorylation | 2 | 2012 | 1713 | 0.130 |
Why?
| Receptors, Androgen | 1 | 2017 | 147 | 0.130 |
Why?
| Gene Knock-In Techniques | 1 | 2016 | 53 | 0.130 |
Why?
| Ovary | 1 | 2017 | 210 | 0.120 |
Why?
| Epithelial Cells | 2 | 2013 | 1065 | 0.120 |
Why?
| Transcriptional Activation | 3 | 2013 | 366 | 0.120 |
Why?
| Inhibitor of Differentiation Protein 1 | 2 | 2011 | 6 | 0.110 |
Why?
| Neoplasm Invasiveness | 1 | 2016 | 485 | 0.110 |
Why?
| Mammary Glands, Human | 1 | 2014 | 64 | 0.110 |
Why?
| 3' Untranslated Regions | 1 | 2014 | 138 | 0.110 |
Why?
| Mice, Knockout | 1 | 2020 | 2871 | 0.110 |
Why?
| Animals | 8 | 2020 | 35360 | 0.110 |
Why?
| Oncogene Proteins | 1 | 2013 | 55 | 0.110 |
Why?
| Mice, Nude | 2 | 2012 | 683 | 0.100 |
Why?
| Protein Kinase Inhibitors | 2 | 2016 | 891 | 0.100 |
Why?
| Humans | 12 | 2020 | 129622 | 0.100 |
Why?
| Neuroblastoma | 1 | 2013 | 154 | 0.100 |
Why?
| Cytostatic Agents | 1 | 2012 | 6 | 0.100 |
Why?
| Transforming Growth Factor beta1 | 1 | 2013 | 157 | 0.100 |
Why?
| Immunohistochemistry | 2 | 2017 | 1698 | 0.100 |
Why?
| Muscle Proteins | 1 | 2013 | 220 | 0.100 |
Why?
| Biomarkers, Tumor | 2 | 2016 | 1181 | 0.090 |
Why?
| LIM Domain Proteins | 1 | 2011 | 17 | 0.090 |
Why?
| Receptors, Steroid | 1 | 2012 | 49 | 0.090 |
Why?
| Microtubule-Associated Proteins | 1 | 2013 | 192 | 0.090 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2012 | 91 | 0.090 |
Why?
| Bone Morphogenetic Proteins | 1 | 2012 | 131 | 0.090 |
Why?
| Morpholines | 1 | 2012 | 122 | 0.090 |
Why?
| RNA, Messenger | 2 | 2016 | 2708 | 0.090 |
Why?
| Mice | 3 | 2020 | 16937 | 0.090 |
Why?
| Cell Cycle | 1 | 2013 | 592 | 0.090 |
Why?
| Cohort Studies | 1 | 2020 | 5420 | 0.080 |
Why?
| Prognosis | 2 | 2016 | 3794 | 0.080 |
Why?
| STAT3 Transcription Factor | 1 | 2012 | 195 | 0.080 |
Why?
| Smad2 Protein | 1 | 2009 | 38 | 0.080 |
Why?
| Nuclear Proteins | 1 | 2013 | 663 | 0.080 |
Why?
| Pyrazoles | 1 | 2012 | 405 | 0.080 |
Why?
| Pyrimidines | 1 | 2012 | 459 | 0.070 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 442 | 0.070 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 769 | 0.070 |
Why?
| Rats | 5 | 2017 | 5499 | 0.070 |
Why?
| Female | 6 | 2020 | 68770 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 1 | 2010 | 2012 | 0.060 |
Why?
| Cell Line | 1 | 2010 | 2781 | 0.060 |
Why?
| Obesity | 1 | 2017 | 2882 | 0.060 |
Why?
| Rats, Wistar | 2 | 2017 | 441 | 0.050 |
Why?
| HEK293 Cells | 2 | 2013 | 697 | 0.040 |
Why?
| Male | 5 | 2013 | 63674 | 0.040 |
Why?
| RNA, Small Interfering | 2 | 2013 | 587 | 0.040 |
Why?
| Phenylthiohydantoin | 1 | 2017 | 44 | 0.030 |
Why?
| Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.030 |
Why?
| Ovariectomy | 1 | 2017 | 137 | 0.030 |
Why?
| Steroids | 1 | 2017 | 158 | 0.030 |
Why?
| Nitriles | 1 | 2017 | 172 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 423 | 0.030 |
Why?
| Postmenopause | 1 | 2017 | 351 | 0.030 |
Why?
| N-Myc Proto-Oncogene Protein | 1 | 2013 | 8 | 0.030 |
Why?
| Testosterone | 1 | 2017 | 372 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2017 | 716 | 0.030 |
Why?
| Interleukin-6 | 1 | 2017 | 720 | 0.030 |
Why?
| Adipose Tissue | 1 | 2017 | 592 | 0.030 |
Why?
| Retinoblastoma Protein | 1 | 2013 | 54 | 0.030 |
Why?
| Autocrine Communication | 1 | 2013 | 43 | 0.030 |
Why?
| Receptors, Transforming Growth Factor beta | 1 | 2013 | 56 | 0.030 |
Why?
| Tretinoin | 1 | 2013 | 130 | 0.030 |
Why?
| Sympathetic Nervous System | 1 | 2013 | 174 | 0.020 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2013 | 119 | 0.020 |
Why?
| Aminosalicylic Acids | 1 | 2012 | 5 | 0.020 |
Why?
| Benzenesulfonates | 1 | 2012 | 19 | 0.020 |
Why?
| Multiprotein Complexes | 1 | 2013 | 155 | 0.020 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 375 | 0.020 |
Why?
| Down-Regulation | 1 | 2013 | 636 | 0.020 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2012 | 182 | 0.020 |
Why?
| MAP Kinase Signaling System | 1 | 2013 | 312 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 359 | 0.020 |
Why?
| Drug Synergism | 1 | 2012 | 371 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 431 | 0.020 |
Why?
| Disease Progression | 1 | 2017 | 2635 | 0.020 |
Why?
| Nerve Tissue Proteins | 1 | 2013 | 570 | 0.020 |
Why?
| Smad3 Protein | 1 | 2009 | 43 | 0.020 |
Why?
| Lentivirus | 1 | 2009 | 53 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2009 | 128 | 0.020 |
Why?
| Gene Silencing | 1 | 2009 | 190 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2017 | 4063 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2013 | 1418 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3973 | 0.020 |
Why?
| Cell Differentiation | 1 | 2013 | 1902 | 0.020 |
Why?
|
|
Wahdan-Alaswad's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|